Vivici Enters U.S. With Precision-Fermented Lactoferrin as It Scales Global Ingredients Platform

New updates have been reported about Vivici.

Vivici is moving aggressively into the U.S. functional ingredients market with the launch of Vivitein™ LF, a precision‑fermented lactoferrin that has achieved self‑affirmed GRAS status, removing a major regulatory hurdle for commercial adoption. The ingredient is positioned to solve chronic supply and cost constraints that have limited traditional dairy‑derived lactoferrin, opening the door for broader use in gut health, performance recovery, and women’s vitality products.

The launch of Vivitein™ LF, the second product in Vivici’s Vivitein™ portfolio after its beta‑lactoglobulin ingredient, signals rapid portfolio expansion since the company’s founding in 2023. Backed by growing demand in the global health and wellness food market—estimated at about $938 billion in 2024 and projected to exceed $2.2 trillion by 2032—Vivici is expanding its manufacturing footprint to build a global supply network and accelerate geographic and segment access for its precision‑fermented proteins.

Vivici’s strategy is to leverage precision fermentation to unlock high‑value dairy bioactives, such as lactoferrin, at scale and with more predictable cost structures than conventional dairy streams. CEO Stephan van Sint Fiet positions the company as an enabler for brands seeking “from within” health solutions, particularly around energy, gut health, and sustained performance, where consumer demand is strongest. By offering a high‑purity, multi‑functional protein with consistent quality, Vivici aims to become a key B2B partner to health and wellness, sports nutrition, and functional food players.

Functionally, Vivitein™ LF targets three major health platforms: microbiome support and gut barrier strength; modulation of low‑grade inflammation associated with repeated exercise; and improved iron mobilisation, with clear relevance for women with low iron levels. These use cases align with premium positioning and could support higher‑margin formulations for Vivici’s customers, reinforcing the company’s ability to compete on value, not just cost. The successful commercialisation of Vivitein™ BLG and now Vivitein™ LF also demonstrates that Vivici can move from R&D to market launch quickly.

To build commercial traction and partnerships in North America, Vivici will showcase Vivitein™ LF and Vivitein™ BLG at Expo West 2026 in Anaheim, giving prospective customers access to prototypes and application support at scale. The combination of regulatory progress, portfolio expansion, and manufacturing build‑out suggests Vivici is transitioning from an early‑stage precision‑fermentation venture into a more fully fledged global ingredients supplier. For executives in food, beverage, and nutrition, Vivici’s progress signals a credible new source of high‑value dairy proteins that can de‑risk supply, support premium pricing, and enable differentiated health‑positioned product pipelines over the medium term.